ArticleBMC medical genomics2025
Unravelling homozygous PLA2G6 variants in Pakistani individuals with diverse clinical manifestations via whole exome sequencing.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Whole Exome Sequencing (WES) was performed on 265 Pakistani individuals with suspected neurodevelopmental disorders, revealing that seven of them carried homozygous mutations in the PLA2G6 gene, which is linked to neurodegenerative diseases such as Infantile Neuroaxonal Dystrophy (INAD) and Parkinson's disease 14 (PD14). These patients presented with a typical cluster of symptoms, including ataxia, gait instability, cognitive decline, motor regression, and psychiatric manifestations like autistic features, impulsive behaviour, and emotional lability. However, the clinical presentation varied across patients, underscoring the phenotypic diversity associated with PLA2G6 mutations. We identified six distinct variants in the PLA2G6 gene (NM_003560.4) across seven affected individuals. These comprised two pathogenic variants (c.2370T > G and c.1427 + 1G > T), three likely pathogenic variants c.929T > A (observed in two patients), c.1591 + 5G > C, and c.2276G > T, and one variant of uncertain significance c.905T > G. All these mutations were predicted to be disease-related by in silico tools, confirming their likely role in disease causation. This study elucidates the variety of clinical features due to PLA2G6 mutations, with manifestations ranging from motor-cognitive to psychiatric features. Our results emphasize the importance of new homozygous variants for the genetic heterogeneity of these diseases. We want to underscore the value of genetic testing in patients with progressive neurodevelopmental signs, like in the case of our patient, which may result in early diagnosis and help in deciding treatment later. Furthermore, this study provides additional insight into genotype-phenotype correlations of PLA2G6-associated diseases and offers directions for future studies to develop tailored therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.